A new study has revealed that the overdiagnosis of prostate cancer may be responsible for vast differences in cancer incidence rates across Europe, with a variation of up to 20-fold between countries. The research, published in the British Medical Journal, shows that while prostate cancer incidence rates fluctuate greatly across the continent, mortality rates display much less variation, with only a five-fold difference between nations.
The findings point to overdiagnosis as a potential driver behind these disparities. Overdiagnosis refers to the identification of tumors that would not have progressed to cause symptoms or death during a man’s lifetime. This can lead to unnecessary treatments, which often carry significant side effects that lower the quality of life for many men.
Overdiagnosis and PSA Testing: A Double-Edged Sword
According to Dr. Salvatore Vaccarella, a scientist from the International Agency for Research on Cancer (IARC) and the study’s lead author, the results suggest that “large overdiagnosis of prostate cancer is occurring as a consequence of opportunistic screening with PSA (Prostate-Specific Antigen) testing.” PSA testing is widely available in routine healthcare visits across Europe, but its use is often opportunistic and inconsistent, leading to overdiagnosis in certain populations.
PSA testing is not part of a standard nationwide screening program in most European countries, with the exception of Lithuania, which adopted such a program in 2006. Instead, men often undergo individual-based, on-demand screenings. While early detection is important, the study highlights how overdiagnosis can lead to overtreatment, causing unnecessary harm and anxiety.
A previous 2009 study found that between 23% and 42% of men flagged by PSA testing would have lived their lives without ever experiencing prostate cancer symptoms or needing a diagnosis.
Prostate Cancer: A Major Health Concern in Europe
Prostate cancer continues to be a major health issue across Europe, accounting for nearly a quarter of all new cancer cases among European men in 2020. The disease led to more than 70,000 deaths that year. However, the risk of overdiagnosis and overtreatment is notably higher with prostate cancer compared to other cancers such as breast, cervical, and colorectal cancer.
The difference in prostate cancer incidence rates across Europe is striking. The study found that incidence rates varied from 89.6 per 100,000 men in 1985 to 385.8 per 100,000 men in 2007, depending on the country. In contrast, mortality rates showed a much smaller variation, ranging from 23.7 per 100,000 men in 1983 to 35.6 per 100,000 men in 2006.
The Importance of Thoughtful Screening Programs
Dr. Vaccarella emphasized the need for a cautious approach to any future prostate cancer screening programs, noting that they must be carefully designed to minimize the harms of overdiagnosis. “Future implementations of prostate cancer screening should come with careful quality assurance, ongoing assessments, and continuous monitoring of both benefits and harms at the population level,” he said.
The study’s authors argue that while PSA testing can detect prostate cancer at an early stage, it can also lead to unnecessary treatments that may not benefit the patient. Prostate cancer is often slow-growing, and many men with the condition may never develop symptoms or require treatment. Overtreatment can result in adverse effects such as incontinence, erectile dysfunction, and psychological distress.
Key Study Findings and Limitations
The study analyzed data from men aged 35 to 84 across 26 European countries over a span of nearly four decades, from 1980 to 2017. The large differences in incidence rates, combined with the smaller variation in mortality rates, strongly suggest that overdiagnosis is playing a significant role in the reporting of prostate cancer cases.
However, the researchers cautioned that the study has several limitations. The data used in the analysis covers different age groups and time periods across countries, which could affect the consistency of comparisons. Furthermore, as an observational study, the results cannot definitively establish cause and effect, meaning further research is needed to draw firm conclusions about the direct relationship between PSA testing and overdiagnosis.
Moving Forward: Reducing Overdiagnosis in Prostate Cancer
As countries continue to grapple with the challenges of prostate cancer detection and treatment, this study provides important insights into the potential pitfalls of widespread PSA testing without clear guidelines. It calls for a balanced approach to prostate cancer screening—one that maximizes the benefits of early detection while minimizing the harms of overdiagnosis and overtreatment.
Public health experts are now focusing on how to improve screening methods and develop guidelines that better differentiate between aggressive cancers that require immediate treatment and slow-growing cancers that may not pose a significant risk.
Related articles:
